Summary
DexCom, Inc. (DXCM) filed its Form 10-Q for the quarterly period ended September 30, 2012, reporting on its financial condition and operational results. The company, a medical device manufacturer focused on continuous glucose monitoring (CGM) systems, continued to experience significant operating losses, a trend consistent since its inception. Despite these losses, DexCom demonstrated revenue growth in its product segment, driven by increased sales volume of its SEVEN PLUS and early adoption of its newer G4 PLATINUM system, which received FDA approval shortly after the reporting period. The company's balance sheet shows a decrease in total assets compared to the prior year-end, primarily due to a reduction in marketable securities, while cash and cash equivalents increased. Significant investments in research and development and selling, general, and administrative expenses continue to outpace revenue growth, contributing to the ongoing net loss. DexCom highlighted its ongoing collaboration efforts with strategic partners in the diabetes technology space and the recent acquisition of SweetSpot to enhance its data management capabilities. Management expressed confidence in its liquidity position, projecting sufficient funds to cover operations through at least September 30, 2013.
Financial Highlights
44 data points| Revenue | $23.10M |
| Cost of Revenue | $14.70M |
| Gross Profit | $8.40M |
| R&D Expenses | $10.30M |
| SG&A Expenses | $15.40M |
| Operating Expenses | $25.70M |
| Operating Income | -$17.30M |
| Interest Expense | $0 |
| Net Income | -$17.30M |
| EPS (Basic) | $-62500.00 |
| Shares Outstanding (Basic) | 276.40M |
Key Highlights
- 1Product revenue increased by 26.4% to $21.1 million for the three months ended September 30, 2012, compared to $16.7 million for the same period in 2011, driven by higher sales volumes.
- 2Despite revenue growth, the company reported a net loss of $17.3 million ($0.25 per share) for the third quarter of 2012, compared to a net loss of $13.3 million ($0.20 per share) in the prior year's third quarter.
- 3Total assets decreased to $102.8 million as of September 30, 2012, from $120.5 million as of December 31, 2011, primarily due to a decrease in short-term marketable securities.
- 4Cash and cash equivalents increased significantly to $4.74 million from $2.55 million, while total cash, cash equivalents, and short-term marketable securities stood at $53.4 million at the end of the quarter.
- 5Research and development expenses increased by 29.2% to $10.6 million for the third quarter of 2012, reflecting ongoing investment in future product generations.
- 6Selling, general, and administrative expenses also rose by 14.3% to $15.1 million for the third quarter of 2012, supporting revenue growth and commercialization efforts.
- 7The company recently received FDA approval for its fourth-generation DexCom G4 PLATINUM system, designed for up to seven days of continuous use, marking a significant advancement in its product line.